The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis

Martina Fabris, Luca Quartuccio, Sandra Lombardi, Marta Saracco, Fabiola Atzeni, Antonio Carletto, Marco Cimmino, Cinzia Fabro, Elena Pontarini, Raffaele Pellerito, Lisa Maria Bambara, Piercarlo Sarzi-Puttini, Maurizio Cutolo, Mariangela Manfredi, Maurizio Benucci, Pia Morassi, Fabio Fischetti, Melissa Padovan, Marcello Govoni, Francesco CurcioElio Tonutti, Salvatore De Vita

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) - 174G>C and the IL-6 receptor (IL-6R) D358A gene polymorphisms were investigated in 158 RA patients treated with rituximab (RTX). One hundred and twenty-eight (81.0%) were RF positive and 126 (79.7%) were anti-CCP positive. Response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR and the ACR criteria. The possible relationship with IL-6 serum levels was also studied. By univariate analysis, lack of response by the EULAR criteria was more prevalent in RA patients with the IL-6 - 174 CC genotypes (39.1%), than in the GC/GG patients (18.5%) (OR 2.83; 95%CI = 1.10-7.27; p = 0.031). A good response was noticed in only one patient (4.3%) with the IL-6 - 174 CC genotype, while it was present in 24.4% of GG/GC cases (p = 0.06). By stepwise multivariate analysis (including RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status and IL-6 genotype as covariates), the IL-6 - 174CC genotype was selected as an independent predictor of no response to RTX by both EULAR and ACR ≥ 50 criteria, while the IL-6R polymorphism resulted as not associated. No definite association between gene polymorphisms and IL-6 serum levels was noticed. Present results suggest a possible role for IL-6 genotyping to better plan treatment with RTX in RA, and larger studies are worthwhile.

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalAutoimmunity Reviews
Volume11
Issue number5
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Interleukin-6
Rheumatoid Arthritis
Genotype
Interleukin-6 Receptors
Therapeutics
ametantrone
Rituximab
Biological Products
Serum
Genes
Cell Survival
B-Lymphocytes
Multivariate Analysis
Biomarkers
Cytokines

Keywords

  • IL-6
  • Pharmacogenetics
  • Rheumatoid arthritis
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Fabris, M., Quartuccio, L., Lombardi, S., Saracco, M., Atzeni, F., Carletto, A., ... De Vita, S. (2012). The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmunity Reviews, 11(5), 315-320. https://doi.org/10.1016/j.autrev.2010.06.012

The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. / Fabris, Martina; Quartuccio, Luca; Lombardi, Sandra; Saracco, Marta; Atzeni, Fabiola; Carletto, Antonio; Cimmino, Marco; Fabro, Cinzia; Pontarini, Elena; Pellerito, Raffaele; Bambara, Lisa Maria; Sarzi-Puttini, Piercarlo; Cutolo, Maurizio; Manfredi, Mariangela; Benucci, Maurizio; Morassi, Pia; Fischetti, Fabio; Padovan, Melissa; Govoni, Marcello; Curcio, Francesco; Tonutti, Elio; De Vita, Salvatore.

In: Autoimmunity Reviews, Vol. 11, No. 5, 03.2012, p. 315-320.

Research output: Contribution to journalArticle

Fabris, M, Quartuccio, L, Lombardi, S, Saracco, M, Atzeni, F, Carletto, A, Cimmino, M, Fabro, C, Pontarini, E, Pellerito, R, Bambara, LM, Sarzi-Puttini, P, Cutolo, M, Manfredi, M, Benucci, M, Morassi, P, Fischetti, F, Padovan, M, Govoni, M, Curcio, F, Tonutti, E & De Vita, S 2012, 'The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis', Autoimmunity Reviews, vol. 11, no. 5, pp. 315-320. https://doi.org/10.1016/j.autrev.2010.06.012
Fabris, Martina ; Quartuccio, Luca ; Lombardi, Sandra ; Saracco, Marta ; Atzeni, Fabiola ; Carletto, Antonio ; Cimmino, Marco ; Fabro, Cinzia ; Pontarini, Elena ; Pellerito, Raffaele ; Bambara, Lisa Maria ; Sarzi-Puttini, Piercarlo ; Cutolo, Maurizio ; Manfredi, Mariangela ; Benucci, Maurizio ; Morassi, Pia ; Fischetti, Fabio ; Padovan, Melissa ; Govoni, Marcello ; Curcio, Francesco ; Tonutti, Elio ; De Vita, Salvatore. / The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. In: Autoimmunity Reviews. 2012 ; Vol. 11, No. 5. pp. 315-320.
@article{a793674098084cf79a2a4094b5aaba58,
title = "The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis",
abstract = "Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) - 174G>C and the IL-6 receptor (IL-6R) D358A gene polymorphisms were investigated in 158 RA patients treated with rituximab (RTX). One hundred and twenty-eight (81.0{\%}) were RF positive and 126 (79.7{\%}) were anti-CCP positive. Response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR and the ACR criteria. The possible relationship with IL-6 serum levels was also studied. By univariate analysis, lack of response by the EULAR criteria was more prevalent in RA patients with the IL-6 - 174 CC genotypes (39.1{\%}), than in the GC/GG patients (18.5{\%}) (OR 2.83; 95{\%}CI = 1.10-7.27; p = 0.031). A good response was noticed in only one patient (4.3{\%}) with the IL-6 - 174 CC genotype, while it was present in 24.4{\%} of GG/GC cases (p = 0.06). By stepwise multivariate analysis (including RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status and IL-6 genotype as covariates), the IL-6 - 174CC genotype was selected as an independent predictor of no response to RTX by both EULAR and ACR ≥ 50 criteria, while the IL-6R polymorphism resulted as not associated. No definite association between gene polymorphisms and IL-6 serum levels was noticed. Present results suggest a possible role for IL-6 genotyping to better plan treatment with RTX in RA, and larger studies are worthwhile.",
keywords = "IL-6, Pharmacogenetics, Rheumatoid arthritis, Rituximab",
author = "Martina Fabris and Luca Quartuccio and Sandra Lombardi and Marta Saracco and Fabiola Atzeni and Antonio Carletto and Marco Cimmino and Cinzia Fabro and Elena Pontarini and Raffaele Pellerito and Bambara, {Lisa Maria} and Piercarlo Sarzi-Puttini and Maurizio Cutolo and Mariangela Manfredi and Maurizio Benucci and Pia Morassi and Fabio Fischetti and Melissa Padovan and Marcello Govoni and Francesco Curcio and Elio Tonutti and {De Vita}, Salvatore",
year = "2012",
month = "3",
doi = "10.1016/j.autrev.2010.06.012",
language = "English",
volume = "11",
pages = "315--320",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis

AU - Fabris, Martina

AU - Quartuccio, Luca

AU - Lombardi, Sandra

AU - Saracco, Marta

AU - Atzeni, Fabiola

AU - Carletto, Antonio

AU - Cimmino, Marco

AU - Fabro, Cinzia

AU - Pontarini, Elena

AU - Pellerito, Raffaele

AU - Bambara, Lisa Maria

AU - Sarzi-Puttini, Piercarlo

AU - Cutolo, Maurizio

AU - Manfredi, Mariangela

AU - Benucci, Maurizio

AU - Morassi, Pia

AU - Fischetti, Fabio

AU - Padovan, Melissa

AU - Govoni, Marcello

AU - Curcio, Francesco

AU - Tonutti, Elio

AU - De Vita, Salvatore

PY - 2012/3

Y1 - 2012/3

N2 - Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) - 174G>C and the IL-6 receptor (IL-6R) D358A gene polymorphisms were investigated in 158 RA patients treated with rituximab (RTX). One hundred and twenty-eight (81.0%) were RF positive and 126 (79.7%) were anti-CCP positive. Response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR and the ACR criteria. The possible relationship with IL-6 serum levels was also studied. By univariate analysis, lack of response by the EULAR criteria was more prevalent in RA patients with the IL-6 - 174 CC genotypes (39.1%), than in the GC/GG patients (18.5%) (OR 2.83; 95%CI = 1.10-7.27; p = 0.031). A good response was noticed in only one patient (4.3%) with the IL-6 - 174 CC genotype, while it was present in 24.4% of GG/GC cases (p = 0.06). By stepwise multivariate analysis (including RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status and IL-6 genotype as covariates), the IL-6 - 174CC genotype was selected as an independent predictor of no response to RTX by both EULAR and ACR ≥ 50 criteria, while the IL-6R polymorphism resulted as not associated. No definite association between gene polymorphisms and IL-6 serum levels was noticed. Present results suggest a possible role for IL-6 genotyping to better plan treatment with RTX in RA, and larger studies are worthwhile.

AB - Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. Being IL-6 a key cytokine for B cell survival, the interleukin-6 (IL-6) - 174G>C and the IL-6 receptor (IL-6R) D358A gene polymorphisms were investigated in 158 RA patients treated with rituximab (RTX). One hundred and twenty-eight (81.0%) were RF positive and 126 (79.7%) were anti-CCP positive. Response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR and the ACR criteria. The possible relationship with IL-6 serum levels was also studied. By univariate analysis, lack of response by the EULAR criteria was more prevalent in RA patients with the IL-6 - 174 CC genotypes (39.1%), than in the GC/GG patients (18.5%) (OR 2.83; 95%CI = 1.10-7.27; p = 0.031). A good response was noticed in only one patient (4.3%) with the IL-6 - 174 CC genotype, while it was present in 24.4% of GG/GC cases (p = 0.06). By stepwise multivariate analysis (including RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status and IL-6 genotype as covariates), the IL-6 - 174CC genotype was selected as an independent predictor of no response to RTX by both EULAR and ACR ≥ 50 criteria, while the IL-6R polymorphism resulted as not associated. No definite association between gene polymorphisms and IL-6 serum levels was noticed. Present results suggest a possible role for IL-6 genotyping to better plan treatment with RTX in RA, and larger studies are worthwhile.

KW - IL-6

KW - Pharmacogenetics

KW - Rheumatoid arthritis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84857501180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857501180&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2010.06.012

DO - 10.1016/j.autrev.2010.06.012

M3 - Article

C2 - 20974296

AN - SCOPUS:84857501180

VL - 11

SP - 315

EP - 320

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 5

ER -